

February 9, 2015

# **Relmada Therapeutics to Present at the 17th Annual BIO CEO & Investor Conference**

## **Presentation on February 9, 2015 at 2:00 p.m. Eastern Time**

NEW YORK, Feb. 9, 2015 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the Company will present at the 17th Annual BIO CEO & Investor Conference on Monday, February 9th at 2:00 p.m. Eastern Time. The conference will take place at the Waldorf Astoria Hotel in New York City.

Sergio Traversa, Chief Executive Officer of Relmada Therapeutics, will provide an overview of the company and recent activities.

### **Webcast Information**

The live and archived webcast of the presentation will be accessible from the Company's website at [www.relmada.com/business-presentation](http://www.relmada.com/business-presentation). Please log in approximately 5-10 minutes before the live event to ensure a timely connection. The archived replay will be available on the Relmada website for one month following the conference.

### **About Relmada Therapeutics, Inc.**

Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of development including LevoCap ER, its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; d-Methadone, its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; BuTab ER, its oral dosage form of the opioid analgesic buprenorphine; and MepiGel, its orphan drug designated topical formulation of the local anesthetic mepivacaine. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit Relmada's website at: [www.relmada.com](http://www.relmada.com).

### **Forward-Looking Statements**

This news release contains "forward-looking statements." These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results

may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

## **Contact**

### Investor Contact:

Michael Becker, SVP of Finance and Corporate Development

Relmada Therapeutics Inc.

Tel: 212-702-7169

[mbecker@relmada.com](mailto:mbecker@relmada.com)

### Media Contact:

Maura McBride

Berry & Company Public Relations

Tel: 212-253-8881

[mmcbride@berrypr.com](mailto:mmcbride@berrypr.com)

Logo - <https://photos.prnewswire.com/prnh/20150113/168770LOGO>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/relmada-therapeutics-to-present-at-the-17th-annual-bio-ceo--investor-conference-300032614.html>

SOURCE Relmada Therapeutics, Inc.